Market Place
Sourcing Support
Outlook`s eye disease drug fails to match Lucentis, sinking stock
30 Nov 2024 //
FIERCE BIOTECH
Lupin completes Phase 3 Trials for Lucentis Biosimilar
06 Aug 2024 //
EXPRESSPHARMA
Roche`s Susvimo Shows Sustained Efficacy In Diabetic Eye Conditions
18 Jul 2024 //
GLOBENEWSWIRE
Italy starts probe into Lucentis biosimilar delay allegation
08 Jun 2024 //
PHARMAPHORUM
Novartis, Roche unit and others face Italy antitrust probe over eye drug
07 Jun 2024 //
REUTERS
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
Xbrane provides reg update on FDA review of its ranibizumab biosimilar candidate
13 Apr 2024 //
PRESS RELEASE
Genentech`s Biologic Lucentis (ranibizumab) Receives Approval in the U.S.
15 Feb 2024 //
FDA
Sandoz buys Coherus` Lucentis biosimilar Cimerli for $170M
22 Jan 2024 //
FIERCE PHARMA
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
04 Oct 2023 //
GLOBENEWSWIRE
Ranibizumab Launch Midas Pharma is the Marketing Authorisation Holder (MAH) of a biosimilar
25 Sep 2023 //
PRESS RELEASE
FDA rejected Outlook Therapeutics` Lucentis rival, & the company`s stock plunged
31 Aug 2023 //
ENDPTS
STADA Arzneimittel`s Ximluci (Ranibizumab) Receives Approval in Europe
20 Jun 2023 //
EMA
Samsung`s Biologic Byooviz (Ranibizumab) Receives Approval in the U.S.
16 Jun 2023 //
FDA
FDA issues new guidance on wet AMD drug development
03 Mar 2023 //
ENDPTS
Roche, Novartis Win Appeal Against Record French Fine
17 Feb 2023 //
BARRONS
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI
13 Feb 2023 //
GLOBENEWSWIRE
STADA, Xbrane get UK MHRA marketing approval for Ximluci biosimilar Lucentis
19 Jan 2023 //
PHARMABIZ
Senator aims to eliminate biosimilar `red tape` with proposal
23 Nov 2022 //
FIERCEPHARMA
Enforcement Report - Week of November 9, 2022
09 Nov 2022 //
FDA
Roche issues voluntary recall for Susvimo over manufacturing issue
22 Oct 2022 //
ENDPTS
Roche has run into a problem with its new eye med Susvimo
18 Oct 2022 //
FIERCEPHARMA
Midas`s Ranivisio (Ranibizumab) Receives Approval in Europe
05 Oct 2022 //
EMA
Coherus to Launch CIMERLI (ranibizumab-eqrn) in the United States on Oc3, 2022
19 Sep 2022 //
GLOBENEWSWIRE
STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar
16 Sep 2022 //
STADA
European Commission grants marketing authorization for Ranivisio
29 Aug 2022 //
BUSINESSWIRE
FDA explains why a new Lucentis biosimilar may be a game-changer
24 Aug 2022 //
ENDPTS
Samsung`s Biologic Byooviz (Ranibizumab-Nuna) Receives Approval in the U.S.
15 Aug 2022 //
FDA
Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod
04 Aug 2022 //
PHARMAPHORUM
FDA Approves First Biosimilar to Lucentis
03 Aug 2022 //
CONTRACTPHARMA
Biogen launch first US biosimilar with Samsung Bioepis
03 Jun 2022 //
FIERCEPHARMA
Teva Receives Approval for First Ophthalmology Biosimilar in Europe
20 May 2022 //
LEXBLOG
Roche’s Susvimo struggles for traction with eye doctors
12 May 2022 //
FIERCEPHARMA
Genentech`s Ranibizumab Receives Supplemental Approval in U.S.
18 Apr 2022 //
FDA
Intas, Axantia ink agreement to commercialise Ranibizumab in Middle East
05 Apr 2022 //
HEALTH ET
Intas Pharma signs supply agreement for Ranibizumab biosimilar in Middle East
05 Apr 2022 //
BIOSPECTRUMASIA
Health Canada Approves Samsung Bioepis and Biogen`s BYOOVIZ, LUCENTIS Biosimilar
10 Mar 2022 //
GLOBENEWSWIRE
New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential
11 Feb 2022 //
BUSINESSWIRE
Novartis targets 20 blockbuster launches by 2026
03 Dec 2021 //
FIERCEPHARMA
Physician Views: Roche`s Susvimo – revolutionary or niche addition to the AMD
01 Nov 2021 //
FIRSTWORDPHARMA
Clinical Trial Research at Wolfe Eye Clinic FDA Approval of Genentech`s Susvimo
27 Oct 2021 //
PRNEWSWIRE
FDA approves Genentech`s eye implant for macular degeneration
23 Oct 2021 //
FIERCEPHARMA
Polpharma Biologics Executives Discuss Ranibizumab Biosimilar
13 Oct 2021 //
CENTERFORBIOSIMILARS
Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe OPT-302
04 Oct 2021 //
GLOBENEWSWIRE
Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab CHS-201
04 Oct 2021 //
GLOBENEWSWIRE
FDA Accepts Review of Polpharma & Bioeq`s BLA of Ranibizumab
04 Oct 2021 //
BUSINESSWIRE
Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe OPT-302
04 Oct 2021 //
GLOBENEWSWIRE
Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab CHS-201
04 Oct 2021 //
GLOBENEWSWIRE
AZ-Daiichi, Biogen-Samsung, Clover and more—Fierce Pharma Asia
24 Sep 2021 //
FIERCEPHARMA
Biogen bags FDA nod for copycat to Roche`s blockbuster Lucentis
21 Sep 2021 //
FIERCEPHARMA
Samsung Bioepis`s Biologic Ranibizumab-Nuna Receives Approval in US
20 Sep 2021 //
FDA
September 2019 was the date when the transformation process started in the API Business Unit of Polpharma.
07 Sep 2021 //
PRESS RELEASE
Samsung Bioepis`s Byooviz (ranibizumab) Receives Approval in Europe
18 Aug 2021 //
EMA
Lupin receives CDSCO committee approval for marketing ranibizumab
09 Jul 2021 //
PHARMABIZ
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab
22 Jun 2021 //
BUSINESSWIRE
SAMSUNG BIOEPIS AND BIOGEN ANNOUNCE FDA FILING ACCEPTANCE OF SB11
18 Nov 2020 //
PRESS RELEASE
EMA accepts application for ranibizumab biosimilar from Samsung Bioepis
23 Oct 2020 //
GABIONLINE
Biogen files application in Europe for Lucentis biosimilar
06 Oct 2020 //
SEEKING ALPHA
Favorable PhIII data for Roche’s Port Delivery System with ranibizumab
23 Jul 2020 //
PRESS RELEASE
